(56 days)
No
The device description and performance studies focus on the physical filtration properties of the device, with no mention of AI or ML technologies.
No.
The device's intended use is for filtering infusion fluids for administration, not for treating a disease or condition.
No
The device is described as an administration set for delivering fluids and filtering them, not for diagnosing conditions or diseases. Its function is to prepare and deliver fluids, not to analyze body parameters or generate diagnostic information.
No
The device description explicitly details physical components like a filter membrane and housing, indicating it is a hardware device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "retention of microorganisms and removal of air and particulate matter from infusion fluids" and for "administration of fluids from a container to a patient's vascular system". This describes a device used in vivo (within the body) for filtering and delivering fluids, not for testing samples in vitro (outside the body) to diagnose a condition.
- Device Description: The description details a filter and administration set for delivering fluids to a patient's vascular system. This aligns with an in vivo medical device.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), detecting analytes, or providing diagnostic information. The function is purely mechanical filtration and fluid delivery.
Therefore, this device falls under the category of a general medical device used for fluid administration and filtration, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
For the retention of microorganisms and removal of air and particulate matter from infusion fluids.
Product codes (comma separated list FDA assigned to the subject device)
FPA
Device Description
The Solution Administration Sets with a 0.2 micron filter product line consists of sterile, non-pyrogenic, single use disposable devices used for the administration of fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. They are indicated for the retention of microorganisms and removal of air and particulate matter from infusion fluids. The filter consists of a 0.2 micron polyethersulfone (PES) solution membrane and 0.1 micron polyvinylidene fluoride air vent membrane enclosed in a copolyester housing. These devices were previously cleared under 510(k) premarket notification K964850 (cleared February 25, 1997)
The basis for this premarket notification is a modification to the 0.2 micron filter currently used in this product line. The modification consists of a change to the solution membrane material. The solution membrane material is changing from a hydrophilic polyethersulfone (PES) to another hydrophilic polyethersulfone (PES). The solution membrane currently used is no longer available and will be replaced with an equivalent material.
These modifications do not impact the intended use or the fundamental scientific technology of the devices. No other materials of construction are being introduced into these devices as part of this update. The product labels are also being updated to revise statements regarding latex and pump device references, add the indications for use statement of the device, and implement other modifications to comply with Baxter's labeling standards.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Patient's vascular system
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following bench tests were conducted to evaluate the effect of the modification to the 0.2 micron filter:
- Air diffusion test
- Bubble point test
- Gravity flow rate test
- Flow rate test post sterile water conditioning
- Flow rate test post parenteral nutrition conditioning
- Bacterial retention test
All tests met the acceptance criteria.
Biocompatibility assessments were conducted in accordance with ISO-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing," for prolonged duration, external communicating device, indirect blood path, and FDA Blue Book Memorandum #G95-1 "Use of International Standard ISO-10993" as recommended in the IV Administration Sets guidance, "Guidance for Industry and FDA Staff: Intravascular Administration Sets Premarket Notification Submissions [510(k)]''. The battery of testing included the following tests:
- Cytotoxicity
- Systemic Toxicity
- Intracutaneous
- Hemolysis
- Pyrogen
- Sensitization
- USP Physicochemical
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract image of three human profiles facing to the right, stacked on top of each other. The profiles are stylized and appear to be made of flowing lines.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 28, 2015
Baxter Healthcare Corporation Mr. Gary Chumbimune Manager, Regulatory Affairs 32650 N Wilson Road Round Lake. Illinois 60073
Re: K153158
Trade/Device Name: Solution Administration Sets with 0.2 Micron Filter Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular Administration Set Regulatory Class: II Product Code: FPA Dated: December 2, 2015 Received: December 3, 2015
Dear Mr. Chumbimune:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours.
Tina
Kiang -S
for Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name
Solution Administration Sets with 0.2 Micron Filter
Indications for Use (Describe)
For the retention of microorganisms and removal of air and particulate matter from infusion fluids.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows the word "Baxter" in a bold, sans-serif font. The word is colored in a dark blue. The image is simple and only contains the company name.
Section 5. 510(k) Summary K153158
October 30, 2015
OWNER:
Baxter Healthcare Corporation One Baxter Parkway Deerfield, Illinois 60015
CONTACT PERSON:
Gary Chumbimune Manager, Regulatory Affairs 32650 N Wilson Road Round Lake, IL 60073 Telephone: (224) 270-3312 Fax: (224) 270-4119
IDENTIFICATION OF THE DEVICE:
Common Name: Intravascular Administration Set Trade Name or Proprietary Name: Solution Administration Sets with 0.2 Micron Filter Classification Panel: 80 General Hospital Classification: Set, Administration, Intravascular (21 CFR 880.5440) Class: Class II
Product Code: FPA
Table 1. Product Codes for Solution Administration Sets with 0.2 Micron Filter
| Code Number | Name |
|---|---|
| 2C6572 | INTERLINK System CONTINU-FLO Solution Set |
| 2H6480 | INTERLINK System Non-DEHP Solution Set with DUO-VENT Spike |
| 2H8671 | CLEARLINK System Non-DEHP Extension Set |
| 1C8363 | Extension Set |
4
Image /page/4/Picture/0 description: The image shows the word "Baxter" in a bold, sans-serif font. The color of the text is a dark blue. The text is slightly slanted to the right, giving it a dynamic appearance. The background is plain white, which makes the text stand out.
PREDICATE DEVICE:
| Device | Company | Predicate 510(k) | Clearance Date |
|---|---|---|---|
| Solution Administration Sets with 0.22 | |||
| Micron Filter | Baxter Healthcare | ||
| Corporation | K964850 | February 25, | |
| 1997 |
Table 2. Predicate Device
DESCRIPTION OF THE DEVICE:
The Solution Administration Sets with a 0.2 micron filter product line consists of sterile, non-pyrogenic, single use disposable devices used for the administration of fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. They are indicated for the retention of microorganisms and removal of air and particulate matter from infusion fluids. The filter consists of a 0.2 micron polyethersulfone (PES) solution membrane and 0.1 micron polyvinylidene fluoride air vent membrane enclosed in a copolyester housing. These devices were previously cleared under 510(k) premarket notification K964850 (cleared February 25, 1997)
The basis for this premarket notification is a modification to the 0.2 micron filter currently used in this product line. The modification consists of a change to the solution membrane material. The solution membrane material is changing from a hydrophilic polyethersulfone (PES) to another hydrophilic polyethersulfone (PES). The solution membrane currently used is no longer available and will be replaced with an equivalent material.
These modifications do not impact the intended use or the fundamental scientific technology of the devices. No other materials of construction are being introduced into these devices as part of this update. The product labels are also being updated to revise statements regarding latex and pump device references, add the indications for use statement of the device, and implement other modifications to comply with Baxter's labeling standards.
INDICATIONS FOR USE:
For the retention of microorganisms and removal of air and particulate matter from infusion fluids.
5
Image /page/5/Picture/0 description: The image shows the word "Baxter" in a bold, blue font. The letters are slightly italicized, giving the word a sense of movement. The color of the text is a vibrant blue, which stands out against the white background.
TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE:
The proposed devices have equivalent technological characteristics as Baxter's currently legally marketed devices cleared under 510(k) premarket notification K964850 (cleared on February 25, 1997). The intended use, design and function of the proposed devices are equivalent to the predicate devices.
DEVICE COMPARISON TABLE:
Table 3 is a device comparison table outlining the differences between the current (predicate) devices and the proposed devices.
| Features | | Current Devices
(Cleared under K964850) | Proposed Devices |
|--------------------------|----------------------|--------------------------------------------------------------------------------------------------------|------------------|
| Intended Use | | For the retention of microorganisms and removal
of air and particulate matter from infusion fluids. | Same |
| Indications for Use | | For the retention of microorganisms and removal
of air and particulate matter from infusion fluids. | Same |
| Sterile | | Yes | Same |
| Non-Pyrogenic | | Yes | Same |
| Single Use | | Yes | Same |
| Materials | | | |
| Spike | | Acrylonitrile Butadiene Styrene | Same |
| Blue Plug | | Synthetic Polyisoprene | Same |
| Cannula | | 304 Stainless Steel | Same |
| Drip Chamber | | Polyvinyl Chloride | Same |
| Check Valve | | Polymethyl Methacrylate and Silicone Rubber | Same |
| 0.2 Micron
Filter | Housing | Copolyester | Same |
| | Solution
Membrane | Polyethersulfone (PES) | Same |
| | Air Vent
Membrane | Polyvinylidene (PVDF) | Same |
| Trilayer
Tubing | Inner Layer | Linear Low Density Polyethylene | Same |
| | Middle
Layer | Polyolefin Adhesive | Same |
| | Outer Layer | Polyvinyl Chloride | Same |
| Tubing | | Polyvinyl Chloride | Same |
| Bushing | | Polyvinyl Chloride | Same |
| Interlink Y-Site | | Copolyester and Synthetic Polyisoprene | Same |
| Clearlink Y-Site | | Polycarbonate and Silicone | Same |
| Male Luer Lock Connector | | Acrylonitrile Butadiene Styrene | Same |
Table 3. Device Comparison
6
Image /page/6/Picture/0 description: The image shows the word "Baxter" in a stylized, bold, blue font. The font appears to be italicized, with the letters slightly slanted to the right. The color of the text is a vibrant blue, and the background is white.
DISCUSSION OF NONCLINICAL TESTS:
Baxter Healthcare Corporation conducts risk analyses and design verification tests based on the result of these analyses. All test results meet their acceptance criteria and support that the proposed devices are appropriately designed for their intended use.
Performance Data:
The following bench tests were conducted to evaluate the effect of the modification to the 0.2 micron filter:
- Air diffusion test ●
- Bubble point test
- Gravity flow rate test ●
- Flow rate test post sterile water conditioning ●
- Flow rate test post parenteral nutrition conditioning
- Bacterial retention test
All tests met the acceptance criteria.
Biocompatibility:
The basis for this premarket notification is a modification to the 0.2 micron filter solution membrane material. The solution membrane material is changing from a hydrophilic polyethersulfone (PES) to another hydrophilic polyethersulfone (PES). No other materials of construction are being introduced into these devices as part of this update.
Biocompatibility assessments were conducted in accordance with ISO-10993, "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing," for prolonged duration, external communicating device, indirect blood path, and FDA Blue Book Memorandum #G95-1 "Use of International Standard ISO-10993" as recommended in the IV Administration Sets guidance, "Guidance for Industry and FDA Staff: Intravascular Administration Sets Premarket Notification Submissions [510(k)]''. The battery of testing included the following tests:
- . Cytotoxicity
- Systemic Toxicity ●
- Intracutaneous ●
7
Image /page/7/Picture/0 description: The image shows the word "Baxter" in a bold, blue font. The font appears to be sans-serif. The word is slightly italicized, giving it a sense of movement. The background is plain white.
- Hemolysis ●
- Pyrogen ●
- Sensitization ●
- USP Physicochemical ●
All other materials found in these devices, that are the subject of this submission, have been previously cleared under Baxter's 510(k) premarket notifications K123868 (cleared January 8, 2013) and K150860 (cleared April 16, 2015).
CONCLUSION:
The non-clinical data demonstrate that the subject device is substantially equivalent and performs comparably to the predicate devices that are currently marketed for the same intended use.